Project description
Cancer therapy with combined radiation and radio waves
Alpha-emitter therapy uses targeted bursts of radiation to destroy cancer cells while sparing most healthy tissue. Yet high doses can sometimes cause side effects, such as pancytopenia (a drop in blood cell counts). The EU-funded TEARF project aims to make this treatment safer and more effective by combining it with radiofrequency (RF) fields – already proven to boost other radiation therapies. By studying how RF fields influence alpha-emitting drugs such as Ra-223, TEARF seeks to enhance cancer cell destruction at lower doses. The result could be a more precise therapy that protects patients while improving treatment outcomes.
Objective
The Effect of Alpha emitters and Radiofrequency Fields on cancer cells in culture.
Alpha emitter radiation therapy involves the use of radionuclides that decay, emitting an alpha particle that kills the cancer cells. Radiopharmaceuticals that emit low levels of alpha particle radiation are used to treat different cancers. Compared to other treatment options such as external beam radiation and chemotherapy, alpha emitter radiation therapy results in better treatment outcome. There are however side effects such as pancytopenia, which may be attributed to the radiation dose administered to the patient. Combination therapy may lead to the use of lower doses of alpha emitters, achieving the desired treatment outcome with reduced side effects. An effective treatment regimen is one that kills the cancer cells with minimal to no normal tissue toxicity. There is, therefore, a need to explore other methods as modulators or modifying agents of the alpha emitter radiation therapy. Radiofrequency fields (RF) have been evaluated for their role as modulators of external beam radiation hence, they are good candidate to assess as modulators of alpha emitter radiation therapy. In the proposed work RF will be evaluated as potential modifying agents for alpha emitter radiation therapy using Ra-223. This project seeks to explore multimodality therapeutic approaches, for better treatment outcomes.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project's classification has been human-validated.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project's classification has been human-validated.
- engineering and technology electrical engineering, electronic engineering, information engineering information engineering telecommunications radio technology radio frequency
- medical and health sciences clinical medicine oncology
- natural sciences chemical sciences nuclear chemistry radiation chemistry
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.4.1 - Widening participation and spreading excellence
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-WIDERA-2024-TALENTS-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
01513 Vilnius
Lithuania
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.